Researchers at The University of Texas at Austin, including Texas ChE’s Dr. George Georgiou and Dr. Jennifer Maynard, successfully culminated years of work when a drug they engineered for the treatment and prevention of inhalational anthrax — the anthrax antitoxin obiltoxaximab — received approval March 21 from the U.S. Food and Drug Administration (FDA). Part of the molecule was engineered at UT Austin before being licensed to New Jersey-based pharmaceutical company Elusys Therapeutics for further development. It will be sold under the name Anthim.
- The Institute Joins Universal Influenza Vaccine Consort...February 14, 2020 - 2:36 PM
- Dr. Everett Stone Competes on Forged in Fire on the History...September 26, 2019 - 4:13 PM
- New cancer treatment uses enzymes to boost immune system...August 29, 2018 - 2:18 PM
- GRA George Delidakis wins Poster Prize at EMBO Antibodies...August 21, 2018 - 6:56 PM